


*A critical look at hot issues in nephrology*

# nephron



#### Editor-in-Chief

**A. Benigni,**  
Bergamo

#### Consulting Editor

**G. Remuzzi,**  
Bergamo

#### Section Editor

**Clinical Practice**  
**D. Warnock,**  
Birmingham, AL

#### Section Editor

**Second Opinion**  
**C.-W. Yang,** Taoyuan

#### Section Editors

**Experimental**  
**Nephrology and**  
**Genetics**

**F. Terzi,** Paris  
**N.V.V.A.M. Knoers,**  
Utrecht

#### Section Editor

**Case Studies in**  
**Genetics**

**M. Vivarelli,** Rome

*Nephron* comprises two sections, which are each under the editorship of internationally recognized leaders and served by specialized and young Associate Editors. Apart from high-quality original research, *Nephron* publishes invited reviews/minireviews on up-to-date topics. Papers undergo an innovative and transparent peer review process encompassing a Presentation Report which assesses and summarizes the presentation of the paper in an unbiased and standardized way. New sections of the Journal are Second Opinion and Case Studies in Genetics. Second Opinion provides a platform for international experts and opinion leaders to cast a critical over published papers dealing with hot topics in clinical and experimental nephrology. The objective of Case Studies in Genetics is to provide clinically relevant examples of the genetic heterogeneity of renal diseases.

The open access journal *Nephron Extra* provides additional contents based on reviewed and accepted submissions to the main journal *Nephron* on [www.karger.com/nne](http://www.karger.com/nne).

#### Nephron

Founded: 1964

Category: Clinical and Basic Research

Field of Interest: Nephrology

Listed in bibliographic services, including:

*PubMed/MEDLINE, Web of Science, Google Scholar,*  
*Scopus, Embase*

2018: Volumes 138, 139, 140

4 issues per volume

Language: English

ISSN 1660-8151

e-ISSN 2235-3186

#### Selected contributions


- L-Carnitine Ameliorates the Decrease of Aquaporin 2 Levels in Rats with Cisplatin-Induced Kidney Injury: **Gao, J.** (Beijing); **Gu, Z.** (Sanya); **Li, M.** (Hefei); **Xu, Y.**; **Gao, Y.**; **Wei, J.**; **Liang, B.**; **Na, Y.** (Beijing)
- Interleukin-17RA Promotes Humoral Responses and Glomerular Injury in Experimental Rapidly Progressive Glomerulonephritis: **Ghali, J.R.**; **O'Sullivan, K.M.**; **Eggenhuizen, P.J.**; **Holdsworth, S.R.**; **Kitching, A.R.** (Clayton, VIC)
- Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy: **Zoja, C.**; **Locatelli, M.**; **Corna, D.**; **Villa, S.**; **Rottoli, D.**; **Nava, V.** (Bergamo); **Verde, R.**; **Piscitelli, F.**; **Di Marzo, V.** (Pozzuoli); **Fingerle, J.** (Basel/ Reutlingen); **Adam, J.-M.**; **Rothenhaeusler, B.**; **Ottaviani, G.**; **Bénardeau, A.** (Basel); **Abbate, M.** (Bergamo); **Remuzzi, G.** (Bergamo/Milan); **Benigni, A.** (Bergamo)
- The Impact of Kidney Development on the Life Course: A Consensus Document for Action The Low Birth Weight and Nephron Number Working Group
- In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hypertension Management in Chronic Kidney Disease? **Tyson, C.C.** (Durham, NC); **Coffman, T.M.** (Durham, NC/Singapore)
- Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal: **Cravedi, P.** (New York, N.Y.)
- Combining Cystatin C and Creatinine Yields a Reliable Glomerular Filtration Rate Estimation in Older Adults in Contrast to  $\beta$ -Trace Protein and  $\beta^2$ -Microglobulin: **Werner, K.**; **Pihlsgård, M.**; **Elmståhl, S.**; **Legrand, H.**; **Nyman, U.**; **Christensson, A.** (Malmö)
- Early Mortality Associated with Inpatient versus Outpatient Hemodialysis Initiation in a Large Cohort of US Veterans with Incident End-Stage Renal Disease: **Arif, F.M.** (Memphis, TN); **Sumida, K.** (Memphis, TN/Kanagawa/Ibaraki); **Molnar, M.Z.** (Memphis, TN/Budapest); **et al.**

More information at

[www.karger.com/nef](http://www.karger.com/nef)



**KARGER**



# nephron

## [www.karger.com/nef](http://www.karger.com/nef)

- Get a free online sample issue
- Get free abstracts
- Read selected articles for free
- Benefit from our online-first policy
- Buy or rent articles individually
- See supplementary material (where available)
- Recommend publications to your library
- Register to our free alert service at [www.karger.com/mykarger](http://www.karger.com/mykarger)



## Submission

Manuscripts in English should be submitted online using the online submission website at:

[www.karger.com/nef](http://www.karger.com/nef)

Should you experience problems with your submission, please contact the Managing Editor:

Manuela Passera  
E-Mail [manuela.passera@marionegri.it](mailto:manuela.passera@marionegri.it)  
Tel. +39 35 421 34 05  
Fax +39 35 31 93 31

## Review

All manuscripts are subject to independent and editorial review. Upon submission, each manuscript is evaluated by the editors and the authors are informed whether the manuscript will be further processed.

Before being forwarded to the Associate Editors and reviewers, the presentation of the paper (organization of the results, quality of the figures, overall writing quality, etc.) is assessed and summarized in a Presentation Report that is fair, professional and standardized. The Presentation Report follows the manuscript throughout the peer review and supports editors, reviewers, and authors in the review process.

The Editors and Associate Editors carefully analyse the comments of the reviewers in order to provide the authors with constructive and realistic requests that should be feasible within the 12 weeks of revision time. The requests made to the authors by the editors are aimed to improve the robustness and significance of the data presented in the manuscript, while curtailing excessive demands in term of effort, time and cost.

## Conditions

Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of *Nephron* and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

More information at [www.karger.com/nef\\_guidelines](http://www.karger.com/nef_guidelines)

## Does your library provide access?

S. Karger AG, P.O. Box  
CH-4009 Basel  
(Switzerland)  
Fax +41 61 306 12 34  
E-Mail [orders@karger.com](mailto:orders@karger.com)

S. Karger Publishers, Inc.  
26 West Avon Road  
P.O. Box 529  
Unionville, CT 06085 (USA)  
Toll free: 1 800 828 5479  
E-Mail [karger@snet.net](mailto:karger@snet.net)

## Dear Librarian

I have reviewed *Nephron* and recommend that our library subscribe to this journal to ensure regular access to this periodical.

Recommended by: \_\_\_\_\_

Department: \_\_\_\_\_

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

## Attention librarians

Karger Publishers would be pleased to send you a complimentary copy for your inspection. Write, fax or e-mail to: any of the addresses on the left.

## Sample copy

Order your free print sample copy of *Nephron*

Send an e-mail to [samplecopy@karger.com](mailto:samplecopy@karger.com)  
Please provide your full name and postal address and the journal title requested.

**KARGER**